

Harpreet S Wasan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5395631/publications.pdf>

Version: 2024-02-01

88
papers

12,039
citations

218381

26
h-index

56606

83
g-index

89
all docs

89
docs citations

89
times ranked

14095
citing authors

#	ARTICLE	IF	CITATIONS
1	Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy. <i>ESMO Open</i> , 2022, 7, 100356.	2.0	7
2	Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 2048-2057.	0.8	65
3	First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study. <i>British Journal of Cancer</i> , 2022, 126, 1548-1554.	2.9	4
4	Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. <i>ESMO Open</i> , 2022, 7, 100477.	2.0	9
5	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 273-284.	0.8	254
6	Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials. <i>Frontiers in Oncology</i> , 2021, 11, 575457.	1.3	5
7	Causes of Death After Colorectal Cancer Diagnosis: A Population-Based Study. <i>Frontiers in Oncology</i> , 2021, 11, 647179.	1.3	12
8	Resveratrol and Its Analogs: Potent Agents to Reverse Epithelial-to-Mesenchymal Transition in Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 644134.	1.3	14
9	The Screening and CONsensus Based on Practices and Evidence (SCOPE) Program—Results of a Survey on Daily Practice Patterns for Patients with mCRC. <i>Current Oncology</i> , 2021, 28, 2097-2106.	0.9	3
10	Transcription factor POU4F2 promotes colorectal cancer cell migration and invasion through hedgehog-mediated epithelial-mesenchymal transition. <i>Cancer Science</i> , 2021, 112, 4176-4186.	1.7	7
11	Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102226.	3.4	8
12	Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3693-3704.	0.8	19
13	Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. <i>Lancet Oncology</i> , 2021, 22, 1468-1482.	5.1	30
14	A population-based study: how to identify high-risk T1 gastric cancer patients?. <i>American Journal of Cancer Research</i> , 2021, 11, 1463-1479.	1.4	1
15	Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. <i>ESMO Open</i> , 2021, 6, 100328.	2.0	15
16	Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE—global randomised trials of selective internal radiotherapy for metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2020, 147, 1078-1085.	2.3	11
17	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. <i>Future Oncology</i> , 2020, 16, 2385-2399.	1.1	96
18	Identification of biomarkers in colon cancer based on bioinformatic analysis. <i>Translational Cancer Research</i> , 2020, 9, 4879-4895.	0.4	5

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Acupuncture-Moxibustion Therapy on Chemotherapy-Induced Leukopenia: A Systematic Review and Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-11.	0.5	5
20	Risk factors for in-hospital mortality in patients with cancer and COVID-19. Lancet Oncology, The, 2020, 21, e406.	5.1	1
21	Risk factors and predictors of lymph nodes metastasis and distant metastasis in newly diagnosed T1 colorectal cancer. Cancer Medicine, 2020, 9, 5095-5113.	1.3	29
22	Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study. Annals of Oncology, 2020, 31, 1160-1168.	0.6	41
23	Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Scientific Reports, 2020, 10, 2083.	1.6	124
24	Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. British Journal of Cancer, 2020, 122, 1760-1768.	2.9	14
25	To be or not to be: whether anti-angiogenic agent combined with immune checkpoint inhibitor is necessary in the treatment of advanced or metastatic renal cell carcinoma. Medical Oncology, 2020, 37, 15.	1.2	5
26	Polymorphisms in Natural Killer Cell Receptor Protein 2D (NKG2D) as a Risk Factor for Cholangiocarcinoma. Journal of Clinical and Experimental Hepatology, 2019, 9, 171-175.	0.4	9
27	Hepatic Resection Following Selective Internal Radiation Therapy for Colorectal Cancer Metastases in the FOXFIRE Clinical Trial: Clinical Outcomes and Distribution of Microspheres. Cancers, 2019, 11, 1155.	1.7	11
28	Value of tumor size as a prognostic factor in metastatic colorectal cancer patients after chemotherapy: a population-based study. Future Oncology, 2019, 15, 1745-1758.	1.1	15
29	Jiedu Sangen Decoction Inhibits the Invasion and Metastasis of Colorectal Cancer Cells by Regulating EMT through the Hippo Signaling Pathway. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-10.	0.5	11
30	The Method of Activating Blood and Dredging Collaterals for Reducing Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-18.	0.5	6
31	<p>Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification</p>. Journal of Pain Research, 2019, Volume 12, 2039-2052.	0.8	58
32	Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2019, 154, 1038.	2.2	154
33	Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600Eâ€“Mutated Colorectal Cancer. New England Journal of Medicine, 2019, 381, 1632-1643.	13.9	918
34	Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology, The, 2019, 20, 663-673.	5.1	773
35	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600Eâ€“Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. Journal of Clinical Oncology, 2019, 37, 1460-1469.	0.8	188
36	Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. Hpb, 2019, 21, 773-783.	0.1	31

#	ARTICLE	IF	CITATIONS
37	Jiedu Sangen Decoction Reverses Epithelial-to-mesenchymal Transition and Inhibits Invasion and Metastasis of Colon Cancer via AKT/GSK-3 β Signaling Pathway. <i>Journal of Cancer</i> , 2019, 10, 6439-6456.	1.2	15
38	3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-88.	1.3	20
39	3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , The, 2018, 19, 562-578.	5.1	133
40	Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2â€“3 randomised trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 162-171.	3.7	47
41	SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. <i>British Journal of Cancer</i> , 2018, 119, 1332-1338.	2.9	19
42	Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 275-281.	0.6	47
43	BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC). <i>Heliyon</i> , 2018, 4, e00804.	1.4	21
44	Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. <i>British Journal of Cancer</i> , 2018, 119, 27-35.	2.9	19
45	Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. <i>European Journal of Cancer</i> , 2018, 102, 31-39.	1.3	25
46	PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer. <i>ESMO Open</i> , 2018, 3, e000379.	2.0	20
47	Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet</i> , The, 2017, 389, 1011-1024.	6.3	1,475
48	Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab. <i>Journal of Medical Genetics</i> , 2017, 54, 567-571.	1.5	4
49	Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 486-499.	5.1	60
50	Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. <i>European Journal of Cancer</i> , 2017, 86, 305-317.	1.3	22
51	The role of cetuximab in converting initially unresectable colorectal cancer liver metastases for resection. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2001-2011.	0.5	18
52	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2017, 18, 1159-1171.	5.1	293
53	Adequate SIRT activity dose is as important as adequate chemotherapy dose â€“ Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e637.	5.1	2
54	Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 1079-1099.	0.6	34

#	ARTICLE	IF	CITATIONS
55	Biomarker prediction of efficacy to vandetanib plus gemcitabine in a phase II double blind multicenter randomized placebo-controlled trial in locally advanced or metastatic pancreatic carcinoma.. Journal of Clinical Oncology, 2017, 35, 4104-4104.	0.8	1
56	A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2017, 35, 342-342.	0.8	1
57	Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer. JMIR Research Protocols, 2017, 6, e43.	0.5	21
58	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 2016, 27, 1386-1422.	0.6	2,545
59	Quality of life, long-term survivors and long-term outcome from the ABC-02 study. British Journal of Cancer, 2016, 114, 965-971.	2.9	39
60	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. BMC Cancer, 2016, 16, 339.	1.1	15
61	MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2016, 34, 4007-4007.	0.8	40
62	ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, LBA4006-LBA4006.	0.8	5
63	ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, LBA4006-LBA4006.	0.8	21
64	Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.. Journal of Clinical Oncology, 2016, 34, 193-193.	0.8	20
65	Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. BMC Cancer, 2015, 15, 764.	1.1	32
66	Ultrasound-guided trans-rectal high-intensity focused ultrasound (HIFU) for advanced cervical cancer ablation is feasible: a case report. Journal of Therapeutic Ultrasound, 2015, 3, 21.	2.2	10
67	Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer. European Journal of Cancer, 2015, 51, 1381-1388.	1.3	19
68	Pancreatic cancer: current management and treatment strategies. Postgraduate Medical Journal, 2015, 91, 601-607.	0.9	22
69	Cost-effectiveness of selective internal radiation therapy using yttrium-90 resin microspheres in treating patients with inoperable colorectal liver metastases in the UK. Journal of Medical Economics, 2015, 18, 797-804.	1.0	10
70	Changes in plasma biomarkers over time in patients (pts) with advanced biliary tract cancer (ABC) treated in the UK ABC-03 randomized phase II trial.. Journal of Clinical Oncology, 2015, 33, 4085-4085.	0.8	11
71	Safety of Redo Hepatectomy for Colorectal Liver Metastases after Selective Interarterial Radiation Therapy: A Case Report. Case Reports in Surgery, 2014, 2014, 1-5.	0.2	2
72	Opportunities for translation: Targeting DNA repair pathways in pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 45-54.	3.3	8

#	ARTICLE	IF	CITATIONS
73	FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. <i>BMC Cancer</i> , 2014, 14, 497.	1.1	76
74	ABC-03: A randomized phase II trial of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine (CisGem) chemotherapy for patients (pts) with advanced biliary tract cancer (ABC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4002-4002.	0.8	3
75	Bevacizumab and combination chemotherapy in rectal cancer until surgery (BACCHUS): A phase II, multicenter, open-label, randomized study of neoadjuvant chemotherapy alone without radiation in patients with MRI-defined high-risk cancer of the rectum not threatening the circumferential margin.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3653-TPS3653.	0.8	0
76	Clinical and molecular characterization of HER2 amplified-pancreatic cancer. <i>Genome Medicine</i> , 2013, 5, 78.	3.6	97
77	FOCUS4: A prospective molecularly stratified, adaptive multicenter program of randomized controlled trials for patients with colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS3645-TPS3645.	0.8	1
78	ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS3649-TPS3649.	0.8	2
79	Integrating Radioembolization With Chemotherapy in the Treatment Paradigm for Unresectable Colorectal Liver Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 293-301.	0.6	21
80	Epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab therapy in combination with oxaliplatin (Ox) and 5FU in first-line treatment of advanced colorectal cancer (aCRC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 3516-3516.	0.8	19
81	Use of epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab (cet) in combination with oxaliplatin (Ox) and 5FU in the first-line treatment of advanced colorectal cancer (aCRC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 32-32.	0.8	14
82	¹⁸ F-fluorothymidine (FLT) PET-CT for early response assessment in advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e21093-e21093.	0.8	0
83	Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. <i>Lancet Oncology</i> , The, 2011, 12, 642-653.	5.1	232
84	Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. <i>New England Journal of Medicine</i> , 2010, 362, 1273-1281.	13.9	3,370
85	A non-intensive gemcitabine-cisplatin regimen in pancreatic cancer significantly improves quality of life and pharmacoeconomics with high response rates. <i>Journal of Clinical Oncology</i> , 2004, 22, 8155-8155.	0.8	0
86	A non-intensive gemcitabine-cisplatin regimen in pancreatic cancer significantly improves quality of life and pharmacoeconomics with high response rates. <i>Journal of Clinical Oncology</i> , 2004, 22, 8155-8155.	0.8	0
87	APC in the regulation of intestinal crypt fission. , 1998, 185, 246-255.		147
88	Hormonal management of prostate cancer. <i>Clinical Endocrinology</i> , 1992, 37, 477-480.	1.2	3